var title_f2_27_2480="Central periph aortic pressures";
var content_f2_27_2480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Central and peripheral aortic pressure tracings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneously recorded pressures from the aortic root (Ao) and femoral artery (FA) demonstrate delayed transmission and a higher systolic pressure in the femoral artery. There is smoothing of the waveform and loss of the dicrotic notch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2480=[""].join("\n");
var outline_f2_27_2480=null;
var title_f2_27_2481="Otoscopic view of right ear with large congenital cholesteatoma";
var content_f2_27_2481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F80406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F80406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Otoscopic view of right ear with large congenital cholesteatoma causing hearing loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2481=[""].join("\n");
var outline_f2_27_2481=null;
var title_f2_27_2482="Lymph node groups body";
var content_f2_27_2482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Lymph node regions in the body",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 477px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2482=[""].join("\n");
var outline_f2_27_2482=null;
var title_f2_27_2483="Urticaria annular lesions";
var content_f2_27_2483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular, edematous, mildly erythematous plaques are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2483=[""].join("\n");
var outline_f2_27_2483=null;
var title_f2_27_2484="Polyethylene glycol electrolyte solution and bisacodyl: Drug information";
var content_f2_27_2484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Polyethylene glycol electrolyte solution and bisacodyl: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/46/23268?source=see_link\">",
"    see \"Polyethylene glycol electrolyte solution and bisacodyl: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HalfLytely&reg; and Bisacodyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Laxative, Bowel Evacuant;",
"     </li>",
"     <li>",
"      Laxative, Stimulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Bowel cleansing:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bisacodyl: 5 mg as a single dose. After bowel movement or 6 hours (whichever occurs first), initiate polyethylene glycol-electrolyte solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Polyethylene glycol-electrolyte solution: 8 ounces every 10 minutes until 2 L are consumed",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kit [each kit contains]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HalfLytely&reg; and Bisacodyl [DSC]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Powder for solution, oral (HalfLytely&reg;): PEG 3350 210 g, sodium bicarbonate 2.86 g, sodium chloride 5.6 g, potassium chloride 0.74 g (2000 mL) [sulfate-free; cherry, lemon-lime, orange flavor] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, delayed release (Bisacodyl): 5 mg (2s) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HalfLytely&reg; and Bisacodyl:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Powder for solution, oral (HalfLytely&reg;): PEG 3350 210 g, sodium bicarbonate 2.86 g, sodium chloride 5.6 g, potassium chloride 0.74 g (2000 mL) [contains 4 flavor packs (each 1 g) cherry, lemon-lime, orange, pineapple flavors]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, delayed release (Bisacodyl): 5 mg (1s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10972919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM220644.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM220644.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F211165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer bisacodyl tablet with water; do not chew or crush tablet. Do not take antacids within 1 hour of taking bisacodyl. Rapidly drinking the polyethylene glycol-electrolyte solution is preferred to drinking small amount continuously. If severe bloating, distention, or abdominal pain occurs, administration should be slowed or temporarily discontinued until symptoms resolve.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bowel cleansing prior to colonoscopy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Fullness (40%), cramping (38%), nausea (34%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Overall discomfort (57%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Gastrointestinal: Vomiting (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylaxis, aspiration, asystole, dermatitis, dizziness, dyspnea, esophageal perforation, hypersensitivity, ischemic colitis, Mallory-Weiss syndrome, pulmonary edema, rhinorrhea, seizure (using the 4 L preparation), syncope, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gastrointestinal obstruction; bowel perforation; toxic colitis; toxic megacolon; gastric retention; ileus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concerns related to adverse effects:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Serious arrhythmias have been reported (rarely) with the use of ionic osmotic laxative products. Use with caution in patients who may be at risk of cardiac arrhythmias (eg, patients with a history of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF, or cardiomyopathy). Consider pre-dose and post-colonoscopy ECGs in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid/electrolyte loss: Fluid and electrolyte disturbances can lead to arrhythmias, seizures, and renal impairment. Advise patients to maintain adequate hydration before, during, and after treatment. If patient becomes dehydrated or experiences significant vomiting after treatment, consider post-colonoscopy lab tests (electrolytes, creatinine, and BUN).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ischemic colitis: Cases of ischemic colitis have been reported; development of severe abdominal pain or rectal bleeding should prompt further evaluation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Generalized tonic-clonic seizures have occurred in patients with no prior history of seizures when using the large volume (4 L) preparation.  Seizures resolved with the correction of fluid and electrolyte abnormalities.  Use caution in patients taking medications which increase the risk for electrolyte abnormalities (eg, diuretics) and/or patients with pre-existing electrolyte abnormalities.  Evaluation of electrolytes pre- and post-colonoscopy is warranted in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Observe unconscious or semiconscious patients with impaired gag reflex or those who are otherwise prone to regurgitation or aspiration during administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment and/or  in patients taking medications that may adversely effect renal function (eg, diuretics, NSAIDs, ACE inhibitors). Patients with impaired renal function who develop severe vomiting should be closely monitored including measurement of electrolytes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: Use with caution in patients with severe ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Evaluate patients with symptoms of bowel obstruction or perforation prior to use. Correct electrolyte abnormalities in patients prior to use. No additional ingredients or flavors (other than the flavor packs provided) should be added to the polyethylene glycol-electrolyte solution.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F211174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Take clear liquid diet the day of and during the bowel preparation; after consuming the solution, avoid drinking large quantities of clear liquids until colonoscopy.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F211170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproductive studies have not been conducted with this combination.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F211182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F211171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink only clear liquids the day of and during the bowel preparation; after consuming the solution, avoid drinking large quantities of clear liquids until colonoscopy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (HalfLytely with Flavor Packs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-210 mg-g (1): $78.67",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F211160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bowel movements; electrolytes, renal function",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F211150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bisacodyl acts on the colonic mucosa to increase peristalsis throughout the large intestine. Polyethylene glycol-electrolyte solution induces catharsis through strong electrolyte and osmotic effects.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F211167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DiPalma JA, McGowan J, and Cleveland M, &ldquo;Clinical Trial: An Efficacy Evaluation of Reduced Bisacodyl Given as Part of a Polyethylene Glycol Electrolyte Solution Preparation Prior to Colonoscopy,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2007, 26(8):113-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/27/2484/abstract-text/17894653/pubmed\" id=\"17894653\" target=\"_blank\">",
"        17894653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DiPalma JA, Wolff BG, Meagher A, et al, &ldquo;Comparison of Reduced Volume Versus Four Liters Sulfate-Free Electrolyte Lavage Solutions for Colonoscopy Colon Cleansing,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2003, 98(10):2187-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/27/2484/abstract-text/14572566/pubmed\" id=\"14572566\" target=\"_blank\">",
"        14572566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10194 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2484=[""].join("\n");
var outline_f2_27_2484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211176\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211189\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211178\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211179\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211162\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211149\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10972919\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211165\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211164\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211187\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211168\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211151\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299901\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211155\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211174\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211157\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211170\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211182\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211171\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422275\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211160\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211150\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211167\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10194\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10194|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/46/23268?source=related_link\">",
"      Polyethylene glycol electrolyte solution and bisacodyl: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_27_2485="Dexlansoprazole: Patient drug information";
var content_f2_27_2485=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dexlansoprazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/9/27799?source=see_link\">",
"     see \"Dexlansoprazole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6884085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dexilant&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10526786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dexilant&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gastroesophageal reflux disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat syndromes caused by lots of stomach acid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat ulcers of the swallowing tube (esophagus).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705183",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dexlansoprazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for soft, brittle bones called osteoporosis (alcohol use, cigarette smoking, other family members with brittle bones, taking drugs to treat seizures, taking steroids).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hip, spine, or wrist fractures may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4042362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on 1 tablespoon (15 mL) of applesauce. Take right away and do not chew granules.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12160 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-57BF54AE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2485=[""].join("\n");
var outline_f2_27_2485=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6884085\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526786\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019164\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019166\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019165\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019170\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019171\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019173\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019168\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019169\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019174\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019175\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/9/27799?source=related_link\">",
"      Dexlansoprazole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_27_2486="Atenolol: Patient drug information";
var content_f2_27_2486=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Atenolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     see \"Atenolol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=see_link\">",
"     see \"Atenolol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tenormin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Atenol&reg;;",
"     </li>",
"     <li>",
"      Ava-Atenolol;",
"     </li>",
"     <li>",
"      CO Atenolol;",
"     </li>",
"     <li>",
"      Dom-Atenolol;",
"     </li>",
"     <li>",
"      JAMP-Atenolol;",
"     </li>",
"     <li>",
"      Mint-Atenolol;",
"     </li>",
"     <li>",
"      Mylan-Atenolol;",
"     </li>",
"     <li>",
"      Nu-Atenol;",
"     </li>",
"     <li>",
"      PMS-Atenolol;",
"     </li>",
"     <li>",
"      RAN&trade;-Atenolol;",
"     </li>",
"     <li>",
"      ratio-Atenolol;",
"     </li>",
"     <li>",
"      Riva-Atenolol;",
"     </li>",
"     <li>",
"      Sandoz-Atenolol;",
"     </li>",
"     <li>",
"      Septa-Atenolol;",
"     </li>",
"     <li>",
"      Tenormin&reg;;",
"     </li>",
"     <li>",
"      Teva-Atenolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used after a heart attack to stop future heart attacks and lengthen life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop tremor (essential).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop performance anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop rebleeding from esophageal varices in cirrhosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bold or forceful actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects caused by drugs that are used for mood.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to atenolol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very weak heart or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect tablets from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11019 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2486=[""].join("\n");
var outline_f2_27_2486=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137426\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137427\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015062\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015064\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015063\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015068\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015069\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015071\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015066\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015067\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015072\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015073\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=related_link\">",
"      Atenolol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=related_link\">",
"      Atenolol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_27_2487="Promethazine: Pediatric drug information";
var content_f2_27_2487=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Promethazine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"    see \"Promethazine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/47/2806?source=see_link\">",
"    see \"Promethazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F214081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Phenadoz&reg;;",
"     </li>",
"     <li>",
"      Phenergan;",
"     </li>",
"     <li>",
"      Promethegan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F214082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bioniche Promethazine;",
"     </li>",
"     <li>",
"      Histantil;",
"     </li>",
"     <li>",
"      Phenergan;",
"     </li>",
"     <li>",
"      PMS-Promethazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phenothiazine Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"      see \"Promethazine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;2 years (use with extreme caution utilizing the lowest most effective dose):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antihistamine: Oral: 0.1 mg/kg/dose (not to exceed 12.5 mg) every 6 hours during the day and 0.5 mg/kg/dose (not to exceed 25 mg) at bedtime as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antiemetic: Oral, I.M., I.V., rectal: 0.25-1 mg/kg (not to exceed 25 mg) 4-6 times/day as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motion sickness: Oral, rectal: 0.5 mg/kg (not to exceed 25 mg) 30 minutes to 1 hour before departure, then every 12 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preoperative analgesia/hypnotic adjunct: I.M., I.V.: 1.1 mg/kg once in combination with an analgesic or hypnotic (at reduced dosage) and with an atropine-like agent (at appropriate dosage).",
"     <b>",
"      Note:",
"     </b>",
"     Promethazine dosage should not exceed half of suggested adult dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sedation: Oral, I.M., I.V., rectal: 0.5-1 mg/kg/dose (not to exceed 25 mg) every 6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antihistamine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral, rectal: 6.25-12.5 mg 3 times/day and 25 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 25 mg, may repeat in 2 hours when necessary; switch to oral route as soon as feasible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antiemetic: Oral, I.M., I.V., rectal: 12.5-25 mg every 4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motion sickness: Oral: 25 mg twice daily with the first dose 30 minutes to 1 hour before departure, then repeat 8-12 hours later as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Obstetrics (labor) as adjunct to analgesia: I.M., I.V.: Early labor: 50 mg; established labor: 25-75 mg in combination with analgesic at reduced dosage; may repeat every 4 hours for up to 2 additional doses (maximum: 100 mg/day while in labor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pre/postoperative analgesia/hypnotic adjunct: I.M., I.V.: 25-50 mg in combination with analgesic or hypnotic (at reduced dosage)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sedation: Oral, I.M., I.V., rectal: 25-50 mg/dose; repeat every 4-6 hours if needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F214053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 25 mg/mL (1 mL); 50 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenergan: 25 mg/mL (1 mL); 50 mg/mL (1 mL) [contains edetate disodium, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal, as hydrochloride: 12.5 mg (12s); 25 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenadoz&reg;: 12.5 mg (12s); 25 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Promethegan&trade;: 12.5 mg (12s); 25 mg (12s); 50 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 6.25 mg/5 mL (118 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 12.5 mg, 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food, water, or milk to decrease GI distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Deep I.M. administration is preferred; avoid I.V. use; in selected patients, promethazine has been administered I.V. diluted to a maximum concentration of 25 mg/mL and infused at a maximum rate of 25 mg/minute; to minimize phlebitis, consider administering over 10-15 minutes; consider limiting initial dose to 6.25-12.5 mg; further dilute the 25 mg/mL strength into 10-20 mL NS; administer through a large bore vein (not hand or wrist) or via a running I.V. line at port farthest from patient's vein. Not for SubQ administration; promethazine is a chemical irritant which may produce necrosis.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F214133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, amsacrine, aztreonam, bivalirudin, ciprofloxacin, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doxorubicin, etoposide phosphate, fenoldopam, filgrastim, fluconazole, fludarabine, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), linezolid, melphalan, ondansetron, oxaliplatin, palonosetron, pemetrexed, remifentanil, sargramostim, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aldesleukin, allopurinol, amphotericin B cholesteryl sulfate complex, cefepime, cefotetan, doxorubicin liposome, foscarnet, furosemide, methotrexate, piperacillin/tazobactam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cefazolin, heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, atropine with meperidine, butorphanol, chlorpromazine, cimetidine, dihydroergotamine, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydroxyzine, meperidine, metoclopramide, midazolam, pentazocine, prochlorperazine edisylate, ranitidine, scopolamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefotetan, ceftriaxone, dexamethasone sodium phosphate, dimenhydrinate, heparin, iodipamide meglumine 52%, iothalamate meglumine 60%, iothalamate sodium 80%, ketorolac, pentobarbital, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Hydromorphone, morphine, nalbuphine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Prior to dilution, store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Solutions in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W are stable for 24 hours at room temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suppositories: Store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Compatible",
"     </b>",
"     (when comixed in the same syringe) with atropine, chlorpromazine, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydromorphone, hydroxyzine hydrochloride, meperidine, midazolam, nalbuphine, pentazocine, prochlorperazine, scopolamine;",
"     <b>",
"      incompatible",
"     </b>",
"     when mixed with aminophylline, cefoperazone (Y-site), ceftriaxone (same syringe), chloramphenicol, dexamethasone (same syringe), dimenhydrinate (same syringe), foscarnet (Y-site), furosemide, heparin, hydrocortisone, methohexital, penicillin G, pentobarbital, phenobarbital, thiopental",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of various allergic conditions and motion sickness, sedative, antiemetic; adjunct to postoperative analgesia and anesthesia (FDA approved in ages &ge;2 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F214135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Promethazine may be confused with chlorproMAZINE, predniSONE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Phenergan&reg; may be confused with PHENobarbital, Phrenilin&reg;, Theragran",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       To prevent or minimize tissue damage during I.V. administration, the Institute for Safe Medication Practices (ISMP) has the following recommendations:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Limit concentration available to the 25 mg/mL product",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Consider limiting initial doses to 6.25-12.5 mg",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Further dilute the 25 mg/mL strength into 10-20 mL NS",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Administer through a large bore vein (not hand or wrist)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Administer via running I.V. line at port farthest from patient's vein",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Consider administering over 10-15 minutes",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Instruct patients to report immediately signs of pain or burning",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sominex: Brand name for promethazine in Great Britain, but also is a brand name for diphenhydrAMINE in the U.S.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F214131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hyper-/hypotension, nonspecific QT changes, orthostatic hypotension, tachycardia,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation akathisia, catatonic states, confusion, delirium, disorientation, dizziness, drowsiness, dystonias, euphoria, excitation, extrapyramidal symptoms, faintness, fatigue, hallucinations, hysteria, insomnia, lassitude, pseudoparkinsonism, tardive dyskinesia, nervousness, neuroleptic malignant syndrome, nightmares, sedation, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema, dermatitis, photosensitivity, skin pigmentation (slate gray), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast engorgement, gynecomastia, hyperglycemia, lactation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Ejaculatory disorder, impotence, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, leukopenia, thrombocytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Abscess, distal vessel spasm, gangrene, injection site reactions (burning, edema, erythema, pain), palsies, paralysis, phlebitis, sensory loss, thrombophlebitis, tissue necrosis, venous thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Incoordination, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, corneal and lenticular changes, diplopia, epithelial keratopathy, pigmentary retinopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, asthma, nasal congestion, respiratory depression",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to promethazine or any component (cross reactivity with other phenothiazines may occur); severe toxic CNS depression or coma; intra-arterial administration; subcutaneous administration; children &lt;2 years; treatment of lower respiratory tract symptoms, including asthma; intra-arterial or subcutaneous administration",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular disease, narrow-angle glaucoma, prostatic hypertrophy, GI or GU obstruction, bone marrow depression, impaired liver function, asthma, peptic ulcer, sleep apnea, and hypertensive crisis; avoid in patients with suspected Reye's syndrome or other hepatic diseases; promethazine may lower the seizure threshold; use with caution in patients with seizure disorders or receiving other medications which may also lower the seizure threshold; promethazine has been reported to cause cholestatic jaundice; may cause photosensitivity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in children &lt;2 years of age due to the potential for severe and potentially fatal respiratory depression",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . A wide range of weight-based doses have resulted in respiratory depression; excessively high doses have been associated with sudden death in children; use with caution and use the lowest effective dose in children &ge;2 years of age and avoid concomitant use with other medications having respiratory depressant effects. Serious tissue injury, including gangrene, has been reported with promethazine injection, regardless of the route of administration",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Preferred route of administration is by deep intramuscular (I.M.) injection. Do not give SubQ or intra-arterially due to severe local reactions including necrosis; rapid I.V. administration may produce a transient fall in blood pressure; slow I.V. administration may produce a slightly elevated blood pressure. Injection may contain sodium metabisulfite which may cause allergic reactions in susceptible individuals. Neuroleptic malignant syndrome (NMS) has been reported with promethazine when used alone or in combination with antipsychotic drugs. Children with dehydration are at increased risk for development of dystonic reactions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F214122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (major), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F214046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Nasal): Promethazine may diminish the vasoconstricting effect of EPINEPHrine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Epinephrine (Racemic): Promethazine may diminish the vasoconstricting effect of Epinephrine (Racemic).  Management: Monitor for diminished vasoconstrictive effects of racemic epinephrine (e.g., diminished efficacy when used for gingival retraction).  This interaction is likely of less concern in patients receiving epinephrine for other purposes (e.g., bronchodilation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Systemic, Oral Inhalation): Promethazine may diminish the vasoconstricting effect of EPINEPHrine (Systemic, Oral Inhalation).  Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Promethazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Promethazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1061424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase dietary intake of riboflavin",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F214049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F214062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Promethazine crosses the placenta. Maternal promethazine use has generally not resulted in an increased risk of birth defects. Platelet aggregation may be inhibited in newborns following maternal use of promethazine within 2 weeks of delivery. Promethazine is used for the treatment of nausea and vomiting of pregnancy (refer to current guidelines). Promethazine is also indicated for use during labor for obstetric sedation and may be used alone or as an adjunct to narcotic analgesics.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10483604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms, mental status; monitor for signs and symptoms of tissue injury (burning or pain at injection site, phlebitis, edema) with I.V. administration",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenothiazine derivative; blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits a strong alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones; competes with histamine for the H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, I.M.: Within 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 25% (due to first pass metabolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 9-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Principally as inactive metabolites in the urine and in the feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/47/2806?source=see_link\">",
"      see \"Promethazine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; notify physician of involuntary movements or feelings of restlessness; may cause dry mouth. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1061422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although promethazine has been used in combination with meperidine and chlorpromazine as a premedication (lytic cocktail), this combination may have a higher rate of adverse effects compared to alternative sedative/analgesics",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Strenkoski-Nix LC, Ermer J, DeCleene S, et al, &ldquo;Pharmacokinetics of Promethazine Hydrochloride After Administration of Rectal Suppositories and Oral Syrup to Healthy Subjects,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2000, 57(16):1499-505.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/27/2487/abstract-text/ 10965395 /pubmed\" id=\" 10965395 \" target=\"_blank\">",
"        10965395",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12735 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-791DB7C3D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2487=[""].join("\n");
var outline_f2_27_2487=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709344\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214081\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214082\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061413\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061406\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214053\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214037\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061417\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214133\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061410\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061416\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214135\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214131\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061421\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061405\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061404\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214122\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214046\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061424\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214049\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214062\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10483604\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061403\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061419\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061420\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061412\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061422\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12735\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12735|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=related_link\">",
"      Promethazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/47/2806?source=related_link\">",
"      Promethazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_27_2488="Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis";
var content_f2_27_2488=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/27/2488/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/27/2488/contributors\">",
"     Arye Rubinstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/27/2488/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/27/2488/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/27/2488/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/27/2488/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/27/2488/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine deaminase (ADA) deficiency (MIM 102700) was the first immunodeficiency in which the specific molecular defect was described. This autosomal recessive genetic disorder typically leads to a severe combined immunodeficiency with dysfunction of T, B, and NK cells (T-B-NK- SCID) that presents in the first few months of life (",
"    <a class=\"graphic graphic_table graphicRef77724 \" href=\"UTD.htm?17/53/18268\">",
"     table 1",
"    </a>",
"    ). However, there are also a few patients with a later onset and relatively milder disease. The wide spectrum of the ADA deficiency phenotype is largely related to the variability in genetic mutations.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, and diagnosis of adenosine deaminase deficiency are presented in this topic review. The treatment of ADA deficiency is discussed separately, as is the related combined immunodeficiency disorder, purine nucleoside phosphorylase deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=see_link\">",
"     \"Adenosine deaminase deficiency: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25637?source=see_link\">",
"     \"Purine nucleoside phosphorylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of severe combined immunodeficiency (SCID) and detailed discussions on other SCID syndromes and combined immunodeficiencies are also covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/10?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): Specific defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADA deficiency has an overall incidence of 1 in 200,000 live births. It accounts for about one-third of all cases of autosomal recessive SCID and approximately 15 percent of all cases of SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine deaminase deficiency is caused by mutations in the ADA gene at 20q13.11 (MIM 608958) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. ADA is an ubiquitous enzyme found in all cells, including red and white blood cells, and in the serum. It catalyzes the deamination of adenosine and deoxyadenosine to inosine and deoxyinosine, which are converted to waste products and excreted. In the absence of functional ADA, there is an intracellular accumulation of adenosine and deoxyadenosine. The replicative activity of the cell dictates the level of sensitivity to these toxic metabolites.",
"   </p>",
"   <p>",
"    Adenosine and deoxyadenosine are also converted to 5'-triphosphates (dATP), which inhibit ribonucleotide reductase and prevent de novo synthesis of nucleotides and deoxynucleotides. There is a decrease in DNA synthesis in replicating cells, because of the depletion of deoxynucleotides. In addition, deoxyadenosine irreversibly binds to and inhibits S-adenosylhomocysteine hydrolase, which also contributes to abnormal DNA synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ADA concentration is highest in the thymus, which probably accounts for the dependence of T cell development and maturation upon this enzyme. The absence of ADA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of purine toxic metabolites may therefore be responsible for the early involution and dysplasia of the thymus observed with this disorder.",
"   </p>",
"   <p>",
"    Several in vitro models have attempted to unravel the mechanisms by which ADA deficiency causes this immune aberration. These models have relied upon two competitive inhibitors of ADA, erythro-9-(2hydroxy-3nonyl) adenine (EHNA) and 2'deoxycoformycin (dCF). In vitro, both compounds suppress lymphocyte mitogenic and antigenic responses that are partially reversed by exogenous ADA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of ADA inhibition was studied in a chimeric",
"    <span class=\"nowrap\">",
"     human/mouse",
"    </span>",
"    fetal thymic organ culture that mimicked an in vivo environment in which toxic metabolites accumulated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/10\">",
"     10",
"    </a>",
"    ]. Thymocyte expansion and differentiation was impaired by ADA inhibition. The decrease in mature thymocytes was primarily due to apoptosis that was associated with accumulation of intracellular dATP. Inhibition of adenosine kinase and deoxycytidine kinase prevented accumulation of dATP and restored thymocyte proliferation and differentiation. T cell apoptosis was abundant in thymi of",
"    <span class=\"nowrap\">",
"     ADA",
"     <sup>",
"      &ndash;/&ndash;",
"     </sup>",
"    </span>",
"    mice, but no increase in apoptosis was detected in the spleen and lymph nodes of these animals, suggesting that the defect is specific to developing thymocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast, human studies in five ADA deficient patients showed that in vitro peripheral blood lymphocyte treatment with ADA metabolites induced a three to fourfold higher proportion of",
"    <sup>",
"    </sup>",
"    apoptotic cells in",
"    <span class=\"nowrap\">",
"     ADA",
"     <sup>",
"      &ndash;/&ndash;",
"     </sup>",
"    </span>",
"    T cells compared with",
"    <sup>",
"    </sup>",
"    normal cells, suggesting that mature ADA deficient T cells are also prone to increased apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ADA-deficient individuals typically have severely reduced numbers of T, B, and NK cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/1\">",
"     1",
"    </a>",
"    ]. However, some patients may retain NK cells and even B cells. Patients with ADA-SCID often have myeloid dysplasia and bone marrow hypocellularity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical spectrum of ADA deficiency has broadened over time as patients with atypical or milder forms have been identified due to the variability of specific genetic mutations.",
"   </p>",
"   <p>",
"    Approximately 90 percent of ADA deficient individuals have a classic severe SCID phenotype in which the disease presents in the first months of life. Most of the remainder may have a \"delayed\" (6 to 24 months) or \"late\" (4 years to adulthood) onset form. Such patients may initially have variable numbers of circulating lymphocytes and some humoral immunity that quickly wanes. As little as 3 percent of residual enzyme activity can maintain nearly functional immunity into adulthood. Thus, a few patients have maintained normal immune function until immunologic decompensation occurs in adulthood and infectious complications bring attention to the diagnosis. Patients with \"partial\" ADA deficiency, who have enzyme activity ranging from 5 to 80 percent of normal, have also been described. In some cases, somatic mutations may even lead to a spontaneous cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     SCID phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most affected patients present with life-threatening infections, chronic persistent diarrhea, and failure to thrive in the first months of life. This phenotype is almost indistinguishable from that of ADA positive SCID. The disease is invariably fatal in the first year or two of life without treatment among these early-onset patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some neonates present with prolonged hyperbilirubinemia and hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/14\">",
"     14",
"    </a>",
"    ]. In others, a severe neonatal graft-versus-host disease is the initial manifestation at birth; this is characterized by a maculopapular rash that becomes desquamative, acute necrotizing hepatitis with jaundice, interstitial pneumonitis, and massive diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial infections affect the lungs, gastrointestinal tract, and skin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/15\">",
"     15",
"    </a>",
"    ], with acute and recurrent infections caused by bacterial, protozoal, fungal, and viral agents. The most frequent organisms and sites of infection are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pneumocystis jirovecii (carinii) pneumonia",
"     </li>",
"     <li>",
"      Oral, esophageal, and intestinal candidiasis",
"     </li>",
"     <li>",
"      Candidal dermatitis of the diaper region",
"     </li>",
"     <li>",
"      Herpetic infections, including cytomegalovirus (CMV), Epstein-Barr virus (EBV), and varicella-zoster virus (VZV)",
"     </li>",
"     <li>",
"      Parainfluenza and enterovirus infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaccination with live vaccines may be fatal. In the past, for example, infants acquired BCG infection or died from disseminated BCG infection following BCG immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transfusion of nonirradiated blood will also invariably result in a fatal graft-versus-host reaction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link\">",
"     \"Transfusion-associated graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination frequently reveals the absence of palpable lymph nodes and small tonsils. Additional findings may include hepatosplenomegaly. Prominence of the costochondral junctions similar to rachitic rosary is sometimes observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present later in life can have similar symptoms and signs as just described. However, milder forms of the disease have also been identified. The severity depends upon the extent of the quantitative and qualitative ADA deficiency. The following observations suggest that ADA deficiency should be considered even in older individuals who present with unexplained lymphopenia and immune deficiency, and that partial ADA deficiency can lead over time to a deterioration of immune function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four children with partial ADA deficiency were described in one case series [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/17\">",
"       17",
"      </a>",
"      ]. These children lacked ADA in red blood cells, but retained variable ADA activity in lymphoid cells. Three of these patients had heat labile ADA mutations that are seen with greater prevalence in the Caribbean and may have a selective advantage with regard to malaria and babesia infections.",
"     </li>",
"     <li>",
"      A child with a partial ADA deficiency was described in whom immune functions deteriorated over time [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 12 year old child was diagnosed with ADA deficiency after presenting with Heck disease (human papilloma virus-induced focal epithelial hyperplasia of the oral mucosa) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one report, an adult form of ADA deficiency was described in 34 and 35 year old sisters who had been lymphopenic from age 17 and 20 years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/20\">",
"       20",
"      </a>",
"      ]. Both had severe CD4 positive lymphopenia, with recurrent bacterial, fungal, and viral infections and chronic lung disease.",
"     </li>",
"     <li>",
"      In another case report, a 39 year old woman was reported with a combined immunodeficiency and lymphopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/21\">",
"       21",
"      </a>",
"      ]. She succumbed to a viral leukoencephalopathy at the age of 40 years.",
"     </li>",
"     <li>",
"      A 28 year old male was diagnosed after his niece died of a severe combined immunodeficiency (SCID) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/21\">",
"       21",
"      </a>",
"      ]. He was healthy and had normal immune function.",
"      <br/>",
"      <br/>",
"      Both the 28 year old male and the 39 year old woman lacked red blood cell ADA activity, but had only modestly elevated deoxyadenosine nucleotides [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4378549\">",
"    <span class=\"h2\">",
"     Neurologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic abnormalities are prominent in ADA deficiency, and include cognitive deficits, behavioral problems, gait abnormalities, hypo- and hypertonia, and sensorineural hearing loss. In a study of 12 ADA-deficient patients who survived hematopoietic cell transplantation (HCT), six demonstrated significant neurologic abnormalities. The authors of that study indicated that the CNS abnormalities were most likely attributed to the metabolic abnormalities of ADA deficiency and not to complications of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=see_link\">",
"     \"Adenosine deaminase deficiency: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a cohort study of 105 patients who underwent HCT for severe congenital immunodeficiencies, ADA-SCID was associated with lower IQ and higher rates of emotional and behavioral difficulties as compared with the other groups [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/23\">",
"     23",
"    </a>",
"    ]. Bilateral sensorineural hearing loss was reported in 7 of 12 patients (58 percent) in a cohort in which all had received HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/24\">",
"     24",
"    </a>",
"    ]. There is a lack of data regarding the effect of PEG-ADA treatment on these neurologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoma is an almost invariably fatal complication that occurs in late presenters and in patients treated successfully with enzyme replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/26\">",
"     26",
"    </a>",
"    ]. As an example, one of the author's patients who responded promptly to enzyme replacement therapy (PEG-ADA) with almost complete resolution of all immune aberrations succumbed at age 14 years from an EBV induced lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/27\">",
"     27",
"    </a>",
"    ]. Lymphomas have also been observed that are unrelated to EBV infection. Although experience is limited, the overall incidence of lymphoma is approximately 20 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27972002\">",
"    <span class=\"h2\">",
"     Dermatofibrosarcoma protuberans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatofibrosarcoma protuberans (DFSP) is a rare malignant skin tumor associated with a t(17;22)(q22;q13) translocation that results in a",
"    <em>",
"     COL1A1",
"    </em>",
"    (type 1 collagen &alpha;-1 chain)-",
"    <em>",
"     PDGFB",
"    </em>",
"    (platelet-derived growth factor &beta;) fusion gene. A high incidence of DFSP, usually with multicentric involvement, is seen in patients with ADA-SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13098?source=see_link\">",
"     \"Dermatofibrosarcoma protuberans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5254318\">",
"    <span class=\"h2\">",
"     Pulmonary alveolar proteinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary alveolar proteinosis (PAP) is a rare disorder caused by accumulation of surfactant-derived components in the lungs. This disorder is seen with high frequency in patients with ADA deficiency, but not other forms of SCID [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/29\">",
"     29",
"    </a>",
"    ]. Adenosine mediates fluid homeostasis and inflammation in the lungs, but the underlying cause of PAP in patients with ADA deficiency is not fully elucidated. PAP is reversible with enzyme replacement therapy and hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=see_link\">",
"     \"Adenosine deaminase deficiency: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Revertant somatic mosaicism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous \"cure\" of ADA deficiency due to revertant somatic mosaicism has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In a case report, a healthy young adult had a history of life-threatening infections, lymphopenia, and failure to thrive as an infant [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/30\">",
"     30",
"    </a>",
"    ]. A B cell line established in infancy lacked ADA activity and had a heteroallelic splice-donor-site mutation and a missense mutation, arg 110-to-gln. The B cell mRNA carried the missense mutation. However, a B cell line established at the age of 16 years expressed 50 percent of normal ADA activity, and 50 percent of the ADA mRNA had the missense mutation while the other 50 percent was normal, suggesting that a somatic mutation or a reversal of the site mutation had occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal individuals, levels of adenosine and other purine nucleosides and deoxynucleosides in the plasma and urine are extremely low or undetectable. The low levels of adenosine and deoxyadenosine in cells, in the plasma, and in the urine are due to rapid equilibration across cell membranes and prompt metabolism.",
"   </p>",
"   <p>",
"    With ADA deficiency, the normal metabolic routes for these compounds are unavailable. Thus, the levels of deoxyadenosine and dATP rise sharply after birth, since the \"detoxification\" by the in utero heterozygote levels of maternal ADA are no longer available, resulting in the following biochemical hallmarks of the disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In red blood cells, there is a massive increase in adenosine, deoxyadenosine, and dATP concentrations and a decrease in ATP values [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The plasma concentrations of adenosine and deoxyadenosine are variable, but are usually elevated to between 0.5 and 10 mM, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the urine, adenosine levels are lower than deoxyadenosine, reflecting the more efficient reutilization of adenosine than deoxyadenosine by phosphorylation in the cells [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The activity of S-adenosylhomocysteine hydrolase in red blood cells is markedly decreased, since this enzyme is inactivated by deoxyadenosine [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immune laboratory values",
"    </span>",
"    &nbsp;&mdash;&nbsp;In ADA negative SCID, the severe T cell deficiency is manifested by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe lymphopenia, with low numbers of CD3+ and CD4+ T cells and low B and NK cells, compared with age matched controls",
"     </li>",
"     <li>",
"      Poor in vitro lymphocyte mitogenic and antigenic responses",
"     </li>",
"     <li>",
"      Absent mixed lymphocyte reactions (MLCs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The expression of B cell abnormalities is less uniform. Most patients are unable to mount specific antibody responses and have variable immunoglobulin deficiencies, including low or absent IgA or IgM levels and low total IgG or IgG subclasses, particularly IgG2. Several patients were found to have markedly increased serum IgE levels. Panhypogammaglobulinemia has also been observed.",
"   </p>",
"   <p>",
"    Additional hematologic laboratory abnormalities may include autoimmune hemolytic anemia, thrombocytopenia, and eosinophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph reveals the absence of a thymic shadow. Radiographs also display flaring of the anterior ribs, pelvic dysplasia, and shortening of the transverse vertebral processes with flattening of their ends (platyspondyly) and thick growth arrest lines [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, the thymus is dysplastic with poor corticomedullary differentiation, small nests of undifferentiated epithelial cells, and absence of Hassall's corpuscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children with ADA negative SCID present with signs and symptoms typical of all children with SCID. These include failure to thrive, life-threatening infections, chronic mucocutaneous fungal infections,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    opportunistic infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'SCID phenotype'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The patient suspected of having SCID of whatever etiology requires the complete evaluation of specific humoral and cellular immunity. Studies include the measurement of immunoglobulin levels, absolute numbers and percentages of lymphocyte subsets (T, B, and NK), and assessment of T cell function. In this situation, T cell function is usually determined by in vitro measurement of responses to mitogens, such as phytohemagglutinin (PHA) and concanavalin A (ConA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link&amp;anchor=H9#H9\">",
"     \"Severe combined immunodeficiency (SCID): An overview\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ADA deficiency SCID is suggested by finding severe T cell deficiency, as expressed by lymphopenia, with low numbers of CD3+ and CD4+ cells, poor in vitro lymphocyte mitogenic and antigenic responses, and absent mixed lymphocyte reactions. Most patients also have marked reduction of B and NK cells.",
"   </p>",
"   <p>",
"    In late presenters, recurrent infection, opportunistic infections, and an unexplained lymphopenia may raise the suspicion of an unusual form of ADA deficiency.",
"   </p>",
"   <p>",
"    The major diagnostic metabolic laboratory findings specific for ADA deficiency, which are also used to monitor treatment results, are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absent ADA levels in lysed erythrocytes",
"     </li>",
"     <li>",
"      A marked increase in dATP levels in erythrocyte lysates (with levels that vary by laboratory)",
"     </li>",
"     <li>",
"      A significant decrease in ATP concentration in red blood cells",
"     </li>",
"     <li>",
"      Absent or extremely low levels of N adenosylhomocysteine hydrolase in red blood cells",
"     </li>",
"     <li>",
"      Increase in 2'-deoxyadenosine in urine and plasma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis can be made by mutational analysis or by evaluation of ADA activity in cultured fibroblasts from amniotic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/9\">",
"     9",
"    </a>",
"    ] and from chorionic villus sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/37\">",
"     37",
"    </a>",
"    ]. Prenatal diagnosis via molecular genetic testing is an option for those families in which the mutations causing ADA deficiency have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/38\">",
"     38",
"    </a>",
"    ]. Amniocentesis is indicated in any pregnancy that follows the birth of a child with ADA deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10180303\">",
"    <span class=\"h2\">",
"     Newborn screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn screening via TRECs may prove an important way to diagnose ADA deficiency early in infancy, prior to the onset of severe infections. TRECs are T-cell receptor excision circles, formed during the differentiation of T cells in the thymus. They serve as a marker for na&iuml;ve T cells in the peripheral blood, and can be enumerated using dried blood spots on newborn screening cards [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/39\">",
"     39",
"    </a>",
"    ]. In 2008, Wisconsin was the first state in the United States to implement a statewide screening program using TRECs. In New York State, an infant with ADA deficiency was identified by the TRECs newborn screening program which started in September 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/40\">",
"     40",
"    </a>",
"    ]. A Japanese study found two patients with ADA deficiency to have low or undetectable TRECs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2488/abstract/41\">",
"     41",
"    </a>",
"    ]. A progressive loss of TRECs was observed in the patient with initially low but detectable TRECs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link&amp;anchor=H6#H6\">",
"     \"Severe combined immunodeficiency (SCID): An overview\", section on 'Newborn screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of adenosine deaminase deficiency includes all other forms of autosomal recessive SCIDs and complete DiGeorge syndrome, although the latter has associated facial and cardiac anomalies that are not seen with ADA deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/10?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): Specific defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=see_link\">",
"     \"DiGeorge syndrome: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenosine deaminase (ADA) deficiency (MIM 102700) is a rare autosomal recessive genetic disorder caused by mutations in the ADA gene at 20q13.11 (MIM 608958). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of functional ADA, there is an intracellular accumulation of adenosine and deoxyadenosine; these products are toxic to lymphocytes. The wide spectrum of the ADA deficiency phenotype is largely related to the variability in genetic mutations. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ADA deficiency typically leads to a severe combined immunodeficiency with dysfunction of T, B, and NK cells (T-B-NK- SCID) that presents in the first few months of life (",
"      <a class=\"graphic graphic_table graphicRef77724 \" href=\"UTD.htm?17/53/18268\">",
"       table 1",
"      </a>",
"      ). However, there are also a few patients with a later onset and relatively milder disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical laboratory findings that also aid in diagnosis include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Absent ADA in lysed erythrocytes and elevated levels of adenosine and deoxyadenosine levels in the urine and plasma",
"     </li>",
"     <li>",
"      Severe T cell deficiency manifested by lymphopenia and poor T cell responses to mitogens and antigens; inability to mount specific antibody responses in most patients, but immunoglobulin levels are variable",
"     </li>",
"     <li>",
"      Absent thymic shadow on chest radiograph",
"      <br/>",
"      <br/>",
"      (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Laboratory findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/1\">",
"      Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997; 130:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/2\">",
"      Hershfield MS. Genotype is an important determinant of phenotype in adenosine deaminase deficiency. Curr Opin Immunol 2003; 15:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/3\">",
"      Wiginton DA, Adrian GS, Friedman RL, et al. Cloning of cDNA sequences of human adenosine deaminase. Proc Natl Acad Sci U S A 1983; 80:7481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/4\">",
"      Wiginton DA, Kaplan DJ, States JC, et al. Complete sequence and structure of the gene for human adenosine deaminase. Biochemistry 1986; 25:8234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/5\">",
"      Jhanwar SC, Berkvens TM, Breukel C, et al. Localization of human adenosine deaminase (ADA) gene sequences to the q12----q13.11 region of chromosome 20 by in situ hybridization. Cytogenet Cell Genet 1989; 50:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/6\">",
"      Markert ML, Norby-Slycord C, Ward FE. A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution. Am J Hum Genet 1989; 45:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/7\">",
"      Hershfield MS, Kredich NM, Ownby DR, et al. In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients. J Clin Invest 1979; 63:807.",
"     </a>",
"    </li>",
"    <li>",
"     Middleton's allergy: Principles and practice, 6th ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St. Louis 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/9\">",
"      Rubinstein A, Hirschhorn R, Sicklick M, Murphy RA. In vivo and in vitro effects of thymosin and adenosine deaminase on adenosine-deaminase-deficient lymphocytes. N Engl J Med 1979; 300:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/10\">",
"      Joachims ML, Marble PA, Laurent AB, et al. Restoration of adenosine deaminase-deficient human thymocyte development in vitro by inhibition of deoxynucleoside kinases. J Immunol 2008; 181:8153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/11\">",
"      Apasov SG, Blackburn MR, Kellems RE, et al. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J Clin Invest 2001; 108:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/12\">",
"      Cassani B, Mirolo M, Cattaneo F, et al. Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood 2008; 111:4209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/13\">",
"      Sokolic R, Maric I, Kesserwan C, et al. Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood 2011; 118:2688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/14\">",
"      Bollinger ME, Arredondo-Vega FX, Santisteban I, et al. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. N Engl J Med 1996; 334:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/15\">",
"      Morgan G, Levinsky RJ, Hugh-Jones K, et al. Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency. Clin Exp Immunol 1987; 70:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/16\">",
"      Heyderman RS, Morgan G, Levinsky RJ, Strobel S. Successful bone marrow transplantation and treatment of BCG infection in two patients with severe combined immunodeficiency. Eur J Pediatr 1991; 150:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/17\">",
"      Hirschhorn R, Tzall S, Ellenbogen A, Orkin SH. Identification of a point mutation resulting in a heat-labile adenosine deaminase (ADA) in two unrelated children with partial ADA deficiency. J Clin Invest 1989; 83:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/18\">",
"      Hirschhorn R, Tzall S, Ellenbogen A. Hot spot mutations in adenosine deaminase deficiency. Proc Natl Acad Sci U S A 1990; 87:6171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/19\">",
"      Artac H, G&ouml;kt&uuml;rk B, Bozdemir SE, et al. Late-onset adenosine deaminase deficiency presenting with Heck's disease. Eur J Pediatr 2010; 169:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/20\">",
"      Shovlin CL, Simmonds HA, Fairbanks LD, et al. Adult onset immunodeficiency caused by inherited adenosine deaminase deficiency. J Immunol 1994; 153:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/21\">",
"      Ozsahin H, Arredondo-Vega FX, Santisteban I, et al. Adenosine deaminase deficiency in adults. Blood 1997; 89:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/22\">",
"      H&ouml;nig M, Albert MH, Schulz A, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 2007; 109:3595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/23\">",
"      Titman P, Pink E, Skucek E, et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood 2008; 112:3907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/24\">",
"      Albuquerque W, Gaspar HB. Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiency. J Pediatr 2004; 144:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/25\">",
"      Gaspar HB. Bone marrow transplantation and alternatives for adenosine deaminase deficiency. Immunol Allergy Clin North Am 2010; 30:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/26\">",
"      Husain M, Grunebaum E, Naqvi A, et al. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase. J Pediatr 2007; 151:93.",
"     </a>",
"    </li>",
"    <li>",
"     Rubinstein A, Albert Einstein College of Medicine, 2004, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/28\">",
"      Kesserwan C, Sokolic R, Cowen EW, et al. Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency. J Allergy Clin Immunol 2012; 129:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/29\">",
"      Grunebaum E, Cutz E, Roifman CM. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency. J Allergy Clin Immunol 2012; 129:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/30\">",
"      Hirschhorn R, Yang DR, Israni A, et al. Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery. Am J Hum Genet 1994; 55:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/31\">",
"      Hirschhorn R, Yang DR, Puck JM, et al. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet 1996; 13:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/32\">",
"      Wada T, Candotti F. Somatic mosaicism in primary immune deficiencies. Curr Opin Allergy Clin Immunol 2008; 8:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/33\">",
"      Cohen A, Hirschhorn R, Horowitz SD, et al. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A 1978; 75:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/34\">",
"      Donofrio J, Coleman MS, Hutton JJ, et al. Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease. J Clin Invest 1978; 62:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/35\">",
"      Simmonds HA, Sahota A, Potter CF, Cameron JS. Purine metabolism and immunodeficiency: urinary purine excretion as a diagnostic screening test in adenosine deaminase and purine nucleoside phosphorylase deficiency. Clin Sci Mol Med 1978; 54:579.",
"     </a>",
"    </li>",
"    <li>",
"     Wolfson JJ, Cross VF. The radiologic findings in 49 patients with combined immunodeficiency. In: Combined immunodeficiency diseases and adenosine deaminase deficiency: A molecular defect, Meuwissen HJ, Pickering RJ, Pollara B, Porter IH (Eds), Academic Press, New York 1975. p.225.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/37\">",
"      P&eacute;rignon JL, Durandy A, Peter MO, et al. Early prenatal diagnosis of inherited severe immunodeficiencies linked to enzyme deficiencies. J Pediatr 1987; 111:595.",
"     </a>",
"    </li>",
"    <li>",
"     Hershfield M. Adenosine deaminase deficiency. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2006 Oct 03 [updated 2009 Jul 14]. file://www.ncbi.nlm.nih.gov/pubmed?term=20301656 (Accessed on February 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/39\">",
"      Routes JM, Grossman WJ, Verbsky J, et al. Statewide newborn screening for severe T-cell lymphopenia. JAMA 2009; 302:2465.",
"     </a>",
"    </li>",
"    <li>",
"     Beth Vogel, New York State Department of Health, January 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2488/abstract/41\">",
"      Morinishi Y, Imai K, Nakagawa N, et al. Identification of severe combined immunodeficiency by T-cell receptor excision circles quantification using neonatal guthrie cards. J Pediatr 2009; 155:829.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3907 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2488=[""].join("\n");
var outline_f2_27_2488=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SCID phenotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other phenotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4378549\">",
"      Neurologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27972002\">",
"      Dermatofibrosarcoma protuberans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5254318\">",
"      Pulmonary alveolar proteinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Revertant somatic mosaicism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immune laboratory values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10180303\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3907\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3907|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/53/18268\" title=\"table 1\">",
"      SCID classification and gene defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=related_link\">",
"      Adenosine deaminase deficiency: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13098?source=related_link\">",
"      Dermatofibrosarcoma protuberans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=related_link\">",
"      DiGeorge syndrome: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25637?source=related_link\">",
"      Purine nucleoside phosphorylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/10?source=related_link\">",
"      Severe combined immunodeficiency (SCID): Specific defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_27_2489="Abd and inguinal intertrigo";
var content_f2_27_2489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80146%7EDERM%2F72073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80146%7EDERM%2F72073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Intertrigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe intertrigo of the abdominal and inguinal folds in an elderly patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtsey of Eva Rawlings Parker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candidal intertrigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous plaque with satellite pustules is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2489=[""].join("\n");
var outline_f2_27_2489=null;
var title_f2_27_2490="Sulfasalazine in the treatment of rheumatoid arthritis";
var content_f2_27_2490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sulfasalazine in the treatment of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/27/2490/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/27/2490/contributors\">",
"     Michael H Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/27/2490/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/27/2490/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/27/2490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/27/2490/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/27/2490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 19, 2008.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylazosulfapyridine (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , Azulfidine) was originally proposed as a treatment for rheumatoid arthritis (RA) because of its antiinflammatory and antimicrobial activities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although early studies suggested a beneficial effect, the drug's efficacy was challenged by the findings of a negative 1948 report, which was influential despite a severely flawed study design [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The introduction of cortisone during this period, an event hailed as a modern medical miracle, further dampened enthusiasm for the use of sulfasalazine in RA.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    was resurrected as a therapeutic agent for rheumatic disorders after beneficial results were reported in a trial performed in the late 1970s and in the first placebo controlled trial in 1983 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Currently, sulfasalazine is approved as safe and effective for the treatment of RA by the Federal Drug Administration (FDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    for the treatment of RA is discussed here. An overview of the management of RA and the use of sulfasalazine in inflammatory bowel disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 30 percent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    is rapidly absorbed by the small bowel and then returned via the enterohepatic circulation into the bile, largely unaltered. Thus, approximately 90 percent of the ingested drug reaches the large intestine as an intact molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. In the colon, sulfasalazine is reduced by the bacterial enzyme azoreductase to sulfapyridine and 5-aminosalicylic acid (5-ASA). Coliform bacteria are therefore necessary to reduce the relatively inactive parent drug to its active moieties. Nearly all of the sulfapyridine is absorbed, while 5-ASA is largely excreted in the feces, thereby explaining its utility in inflammatory bowel disease.",
"   </p>",
"   <p>",
"    Sulfapyridine is subsequently metabolized in the liver via hydroxylation and acetylation. The half-life of these components is prolonged in slow acetylators, a property which may affect toxicity but not efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. No major drug-drug interactions have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies directly comparing the efficacy of sulfapyridine with 5-ASA suggest that, unlike in inflammatory bowel disease in which 5-ASA is the active metabolite, sulfapyridine is the active moiety in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Sulfapyridine may have disease-modifying effects since its administration is associated with decreases in the erythrocyte sedimentation rate and serum concentrations of C-reactive protein [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of action of sulfapyridine in RA has not been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/8\">",
"     8",
"    </a>",
"    ]. Since sulfapyridine is a sulfonamide, an antibacterial effect has been entertained; however, the observation that other sulfonamides are ineffective in RA makes this hypothesis unlikely. One 24-week study, for example, directly compared sulfapyridine (1.25",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    with cotrimoxazole (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , 480 mg TID) in patients with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/13\">",
"     13",
"    </a>",
"    ]. Disease activity was either unchanged or had worsened among patients treated with cotrimoxazole; by comparison, improvement was observed in those administered sulfapyridine. Sulfapyridine may also reduce secretions of inflammatory cytokines such as IL-8 and MCP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, a positive effect due to the parent molecule alone cannot be entirely excluded. Several investigators have studied the parent molecule and have determined several plausible mechanisms of action. As an example, increased production of adenosine at sites of inflammation has been suggested to be an antiinflammatory property of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    that it shares with another effective antirheumatic drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another possible mode of action is the inhibition of nuclear factor kappa B (NFkB). This protein, which is also suppressed by glucocorticoids, induces the transcription of central mediators of the immune response. An in vitro study found that the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    strongly inhibited nuclear factor kappa B-dependent transcription in colonic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/16\">",
"     16",
"    </a>",
"    ]. Interestingly, these actions were unique to sulfasalazine, and were not observed with sulfapyridine or 5-ASA, thereby suggesting that the parent molecule may have important antiinflammatory properties. Sulfasalazine may also inhibit osteoclast formation via modulatory effects on the receptor activator of NFkB (RANK), osteoprotegerin (OPG) and RANK-ligand [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/17\">",
"     17",
"    </a>",
"    ]. There may be additional immunosuppressive effects. Sulfasalazine, for example, inhibits tumor necrosis factor-alpha expression via apoptosis of macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/18\">",
"     18",
"    </a>",
"    ]. Finally, sulfasalazine and its metabolites appear to suppress B cell, but not T cell, function [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the adverse drug reactions described for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    are similar in patients with and without RA. The side effects are either idiosyncratic (eg, hypersensitivity or immune-related) or dose-related [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiosyncratic effects include skin reactions, hepatitis, pneumonitis, agranulocytosis, and aplastic anemia. When such reactions occur, the drug should be immediately stopped and the patient not rechallenged.",
"     </li>",
"     <li>",
"      Dose-related side effects include gastrointestinal upset, central nervous system symptoms, and some less severe hematologic toxicities. Symptoms and laboratory findings of such involvement include anorexia, headache, nausea, vomiting, diarrhea, gastric distress, leukopenia, hemolytic anemia, and a megaloblastic anemia. These problems may resolve with dose reduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse reactions are common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    . Approximately 20 to 25 percent of patients withdraw from clinical trials because of intolerable side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/3\">",
"     3",
"    </a>",
"    ]; two-thirds of such withdrawals result from symptoms due to gastrointestinal and central nervous system toxicity and approximately 4 to 5 percent because of rash [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Liver function abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    may induce a specific syndrome characterized by fever, rash, and markedly abnormal liver function tests. Among such patients, the drug should be immediately discontinued, and the patient should not be rechallenged [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients should be warned about the possible induction of this syndrome since it may be mistaken and ignored as an intercurrent viral illness.",
"   </p>",
"   <p>",
"    Increased serum aminotransferase levels with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    may be more likely to develop in certain settings, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with serologic evidence of chronic viral hepatitis &mdash; When",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      was given to 9 and 18 patients with and without serologic evidence of chronic hepatitis B or C virus infection, respectively, an increase in serum aminotransferase levels was more common in those chronically infected (56 versus 17 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Concomitant use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      &mdash; An increased risk of transaminase elevation was noted when sulfasalazine and isoniazid were used in the setting of tuberculosis prophylaxis in patients with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one case series, the frequency of serious hepatotoxicity with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      was estimated at 0.4 percent of all treated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Leukopenia and agranulocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects upon white cells resulting from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    may be, as noted above, either idiosyncratic or dose-related. Although most episodes of leukopenia, which occur in 1 to 2 percent of patients, are mild and transient, life-threatening agranulocytosis may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Serious episodes of agranulocytosis are usually observed within the first three months and often within the first six weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. Bone marrow recovery occurs in the majority of such patients within one to two weeks of drug discontinuation.",
"   </p>",
"   <p>",
"    Distinguishing the different types of leukopenia is very important. Agranulocytosis caused by a hypersensitivity reaction requires drug discontinuation without rechallenge; by comparison, some investigators feel that benign leukopenia can be treated with dose reduction. Agranulocytosis is characterized by a falling neutrophil count or levels below",
"    <span class=\"nowrap\">",
"     2000/mm3.",
"    </span>",
"   </p>",
"   <p>",
"    Concurrent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    may result in a greater depression of neutrophil counts than occurs with the use of either agent alone. This was noted in a 2005 FDA warning in the prescribing information for etanercept which stated that the combination resulted in a mild decrease in mean neutrophil counts when compared to groups treated with etanercept or sulfasalazine alone. However, the clinical significance of this finding is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Megaloblastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     Sulfasalazine",
"    </a>",
"    inhibits transport of reduced",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    across cell membranes in an in vitro model [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/27\">",
"     27",
"    </a>",
"    ]. This effect could cause intracellular folate deficiency and contribute to the megaloblastic anemia sometimes noted as an adverse effect of sulfasalazine therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gender-specific effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some men treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    experience oligospermia and infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/7\">",
"     7",
"    </a>",
"    ]. These complications are entirely reversible with drug discontinuation.",
"   </p>",
"   <p>",
"    Most clinicians feel that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    is safe in women who may become pregnant. In addition, a survey of pregnancies in treated and nontreated patients with inflammatory bowel disease revealed no differences among exposed as compared to nonexposed women. Sulfasalazine is currently listed as a \"category B\" agent for pregnancy (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of adverse effects appears to be at least partly genetically determined. As an example, among 144 Japanese patients with RA treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , those with N-acetyltransferase genotypes that resulted in slow acetylation of sulfasalazine were more likely to have a side effect than fast acetylators of sulfasalazine (63 percent and 8 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have demonstrated possible relationships between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    use and the development of granulomatosis with polyangiitis (Wegener&rsquo;s), reversible encephalopathy and Epstein Barr virus-associated hypersensitivity syndrome and hemophagocytic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite these adverse effects,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    is relatively well tolerated by most patients with RA. One study evaluated the side effects and long-term usage of sulfasalazine among several hundred patients with RA in whom the drug was administered as a first-line agent for early disease (defined as less than 12 months disease duration and no prior use of disease-modifying antirheumatic drugs) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/32\">",
"     32",
"    </a>",
"    ]. A retention rate of 50 percent at two years was observed among patients administered sulfasalazine as compared to only 20 percent for those given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    . Forty-seven of 186 subjects (25 percent) withdrew because of adverse drug reactions, the majority within the first three months of the initiation of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MEASURES TO MINIMIZE SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse reactions resulting from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    may be diminished by the slow initiation of therapy, drug desensitization among those with sensitivity reactions, and serial monitoring of specific laboratory tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with other investigators that a gradual increase in dosage should be performed to minimize potential toxicity when beginning",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/32\">",
"     32",
"    </a>",
"    ]. A starting dose of 500 mg per day should be used for the first week; the dose is subsequently increased by 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    on a weekly basis until a dose of 2.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    is achieved. The dose can be lowered to 1500 or 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if the patient develops mild toxicity. Among those who fail to respond to 2.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and are without intolerable side effects, the dose can be increased to a maximum of 3.0",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    usually in divided doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with potential sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , desensitization can be accomplished with relative ease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/33\">",
"     33",
"    </a>",
"    ]. A desensitization protocol published in the Physicians Desk Reference recommends starting with a 50 mg dose, which is doubled every four to seven days if tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/7\">",
"     7",
"    </a>",
"    ]. We recommend consultation with an allergist prior to the initiation of such a trial. Desensitization is primarily performed in patients with a history of rash to another sulfonamide; it should",
"    <strong>",
"     not",
"    </strong>",
"    be attempted in patients with a history of agranulocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete blood cell counts and liver function tests should be performed at the initiation of therapy. Subsequent monitoring should be performed every two weeks during the first three months, then monthly for the second three months, and every three months thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial therapeutic benefits with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    as monotherapy have been demonstrated unequivocally in multiple well-designed placebo controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/6,34-38\">",
"     6,34-38",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study randomized 80 patients with early RA (symptomatic disease for 12 months) to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      or placebo for 48 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/35\">",
"       35",
"      </a>",
"      ]. Compared to placebo, sulfasalazine reduced clinical and laboratory evidence of disease and scintigraphic joint activity.",
"     </li>",
"     <li>",
"      In another study of 105 patients with early RA randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      or placebo for six months, a significant improvement in the number of involved joints, the erythrocyte sedimentation rate, and indices of disease activity was observed in patients who received active therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of 8 placebo controlled, randomized trials, which included 552 subjects who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      and 351 who received placebo, reported that active therapy was significantly more effective than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/37\">",
"       37",
"      </a>",
"      ]. Compared to placebo, sulfasalazine reduced the duration of morning stiffness (61 versus 33 percent, p=0.008), the number of painful joints (59 versus 33 percent, p=0.004), number of swollen joints (51 versus 26 percent, p&lt;0.0001), and the amount of joint pain (42 versus 15 percent, p&lt;0.0001)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    therapy alone can retard the rate or prevent the development of erosive disease is incompletely answered. Studies from two major centers found a beneficial effect with sulfasalazine on the rate of new erosion development in the first three years of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. As an example, one report of 60 patients randomized to either sulfasalazine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    therapy for 48 weeks found a significantly lower number of erosions among those treated with sulfasalazine (p &lt; 0.02) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/40\">",
"     40",
"    </a>",
"    ]. Although these studies were imperfect, concurrent findings of a decreased erythrocyte sedimentation rate and serum concentration of C-reactive protein lend support to a possible disease-modifying effect with sulfasalazine therapy.",
"   </p>",
"   <p>",
"    The most compelling evidence for a true disease-modifying effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    is derived from an international study of 358 patients with early RA who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , sulfasalazine, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/42\">",
"     42",
"    </a>",
"    ]. Both active agents were equally superior to placebo in slowing radiographic progression and improving joint swelling. Analysis of two-year data showed that improvements in physical function were sustained over 24 months of successful treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Relative efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies assessing the relative efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    compared with other disease-modifying antirheumatic drugs are problematic because of the large number of patients required to show statistically significant effects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/44\">",
"     44",
"    </a>",
"    ]. Despite this difficulty, the results of multiple clinical trials permit the following conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/3,7,45,46\">",
"     3,7,45,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      is as effective as intramuscular gold and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      is more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , oral gold, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies using drug survival curves, another measure of drug effectiveness, have found that 25 percent of patients remain on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/3\">",
"     3",
"    </a>",
"    ]; this rate is superior to the survival curves for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    and oral gold, but is not different from intramuscular gold and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    is unclear. This question was directly addressed in at least two controlled, prospective trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first randomly assigned 105 patients with RA to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      alone (2 to 3",
"      <span class=\"nowrap\">",
"       g/day),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      alone (7.5 to 15",
"      <span class=\"nowrap\">",
"       mg/week),",
"      </span>",
"      or both drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/47\">",
"       47",
"      </a>",
"      ]. Enrolled patients had early onset RA (defined as disease duration of less than 12 months), were all rheumatoid factor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      HLA-DR1 or -DR4 positive, and were followed for 52 weeks. All three regimens were equally effective, although a trend in favor of combination therapy was observed. However, since methotrexate is currently used at higher doses when clinically indicated, the relative effectiveness of either medication alone may not have been adequately addressed in this study. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"       \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A second study of similar design randomly assigned 205 patients with early RA to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      alone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      alone, and the combination of both drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/48\">",
"       48",
"      </a>",
"      ]. No statistically significant differences were apparent when the clinical response rates (using EULAR or ACR criteria) or the progression of radiographic damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is generally used as first-line therapy in patients with early moderately or severely active RA because of a better benefit-to-toxicity ratio. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study compared extracts of the medicinal plant Tripterygium wilfordii Hook F (TwHF), used in traditional Chinese medicine to treat inflammatory diseases, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      to treat active rheumatoid arthritis. Patients in the TwHF group had significantly greater ACR20 responses than those in the sulfasalazine group at week 24. However, at 24 weeks, only 62 percent of TwHF patients and 41 percent of sulfasalazine patients remained in the study [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with many therapeutic interventions, a belief in the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    may have an important impact upon the physician and patient's perception of its clinical benefit. One enthusiast has stated that the drug has a more rapid onset of action than other agents, is well tolerated, and the dose can and should be increased to a maximum level of 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, although sulfasalazine is no panacea, supporters feel this agent has the capacity to [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/44,50\">",
"     44,50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Manage symptoms",
"     </li>",
"     <li>",
"      Retard erosive disease",
"     </li>",
"     <li>",
"      Enhance quality of life",
"     </li>",
"     <li>",
"      Regress nodules",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, the nodules and vasculitis routinely observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy do not appear to occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared with other drugs, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    as a single agent for the treatment of RA is probably less popular in the United States than in Europe, largely due to historic and cultural factors. Because of the paucity of studies directly comparing the efficacy of sulfasalazine with other agents, it is difficult to currently recommend one agent over another. The choice of therapy should depend upon the treatment goals for and the risk profile of the individual patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unlikely that the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , whether as monotherapy or in combination with other nonbiologic DMARDs, will result in patients achieving a DAS28 remission after an initial failure of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/51\">",
"     51",
"    </a>",
"    ]. Among patients in the BeSt trial, who failed to achieve remission using MTX monotherapy, 78 percent also failed upon switching to or adding sulfasalazine, and 64 percent failed on the combination of sulfasalazine with MTX and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy for RA involving multiple disease-modifying antirheumatic agents is presently favored over single agent \"sawtooth\" therapy (a strategy in which single agents are substituted based upon patient response) because of mostly perceived and theoretical advantages. Since the pathophysiology of RA involves multiple inflammatory pathways, each of which can lead to joint destruction, combination therapy aimed at modifying different inflammatory pathways has the greatest likelihood of being clinically successful in reducing inflammation. In addition, combination therapy permits the use of lower doses of individual disease-modifying antirheumatic agents, thereby possibly resulting in less toxicity. The most commonly used nonbiologic drug combinations are the three-drug combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and the two drug combinations: methotrexate-hydroxychloroquine, methotrexate-sulfasalazine, and methotrexate-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A benefit of combination over individual therapy has been convincingly observed in one study, which included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    in multiple treatment arms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/52\">",
"     52",
"    </a>",
"    ]. This well-controlled, prospective study of 102 patients found that triple therapy with sulfasalazine (500 mg BID),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (7.5 to 17.5 mg per week, titrated for response), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (200 mg BID) was superior to methotrexate alone or sulfasalazine plus hydroxychloroquine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/52\">",
"     52",
"    </a>",
"    ]. The primary endpoint was at least 50 percent improvement at nine months, a benefit that had to be sustained for two years without the development of significant drug toxicity. The proportion who remitted with triple-agent therapy was significantly greater the other regimens ( 77, 40, and 33 percent, respectively). However, there are two important potential limitations to this trial related to study design: the dose of sulfasalazine was limited to 1",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    which probably underestimated its efficacy, and the patient selection process (prior poor response to at least one previous disease-modifying antirheumatic drug) may have influenced the results.",
"   </p>",
"   <p>",
"    Another study compared the efficacy of treatment with the same triple agent regimen against treatment with just two agents, either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    or methotrexate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/53\">",
"     53",
"    </a>",
"    ]. The investigators demonstrated superior efficacy of the triple combination over double therapy. However, it was also noted that the combination of methotrexate and sulfasalazine was less effective than methotrexate combined with hydroxychloroquine. This lack of an additive or synergistic effect may be due to inhibition by sulfasalazine of MTX uptake at the reduced folate carrier, the dominant cell membrane transporter for natural folates and methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of other reports also suggest that combination therapy, including the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , may be superior to single agent therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The COBRA (Combinatietherapie Bij Reumatoide Artritis) trial was a double-blind trial randomly assigned 155 patients with early onset RA to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      alone or to triple therapy consisting of sulfasalazine (2",
"      <span class=\"nowrap\">",
"       g/day),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (7.5",
"      <span class=\"nowrap\">",
"       mg/week),",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (initial dose of 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      which was lowered over six weeks to 7.5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/54\">",
"       54",
"      </a>",
"      ]. Prednisolone and methotrexate were withdrawn at week 28 and 40, respectively. Evaluation of therapeutic efficacy was assessed via a pooled index of five disease activity measures and radiographic outcomes. At week 28, trial therapy resulted in significant clinical benefits as determined by the pooled index when compared to sulfasalazine alone. In addition, 72 and 49 percent of patients treated with combination therapy and sulfasalazine alone had improved, respectively. These benefits were not statistically significant once prednisolone was withdrawn, and the clinical differences between the groups were unchanged after methotrexate was stopped. Nevertheless, radiographic benefits were significantly greater with early aggressive therapy with three drugs than with sulfasalazine alone at multiple time periods (weeks 28, 56, and 80). A cost analysis demonstrated that the COBRA format adds additional disease control at lower or equal cost to sulfasalazine alone in early rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/59\">",
"       59",
"      </a>",
"      ]. Eleven-year follow-up data demonstrated that initial COBRA combination therapy resulted in lower mortality when compared with initial sulfasalazine monotherapy. There was also a suggestion of long-term disease modification because of slower progression of joint damage [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another trial, forty patients with RA unresponsive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      alone were randomized to combination therapy consisting of sulfasalazine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or to methotrexate alone [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/55\">",
"       55",
"      </a>",
"      ]. At 24 weeks, combination therapy resulted in a significant decrease in disease activity compared to methotrexate alone. No difference in toxicity was observed between the two treatment groups.",
"     </li>",
"     <li>",
"      In the MASCOT study, combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      was shown to be more effective than monotherapy with either drug in patients who had had a suboptimal response to sulfasalazine. There was no significant increase in toxicity in the combination group [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The efficacy of combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      was compared to that of therapy with a single agent (beginning with sulfasalazine) in a study that randomly assigned 199 Finnish patients with early active RA and followed them for two years (FIN-RACo trial) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/58\">",
"       58",
"      </a>",
"      ]. A significantly greater proportion of patients receiving combination therapy attained a clinical remission than those on monotherapy (37 percent versus 18 percent, respectively). The increase in radiographic damage was greater in the monotherapy group. Radiographic outcomes continued to be better in the combination group during five years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/62\">",
"       62",
"      </a>",
"      ]. At eleven-year follow-up, the combination group still demonstrated statistically significant higher rates of modified minimal disease activity, as well as ACR remission than their monotherapy counterparts. HAQ scores, however, were not statistically different [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      was one of multiple agents used in a trial that compared \"tight-control\" to routine care of patients with RA (TICORA). Tight control was obtained by monthly visits with formal disease activity measurements, up to three intraarticular joint injections, and escalation of DMARD therapy according to a protocol that included sulfasalazine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , and sodium aurothiomalate [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/57\">",
"       57",
"      </a>",
"      ]. Routine care involved clinic visits every three months with no formal disease activity measurements. DMARD treatment was given or changed based on the discretion of the attending rheumatologist. All patients were also seen at a separate assessment clinic by a blinded metrologist. The primary outcome measures of fall in disease activity score and proportion of patients with good response (by EULAR definition) were significantly greater in the tight control group compared to the routine care group.",
"     </li>",
"     <li>",
"      A similar study compared tight control using step-up therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      for three months, then",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , then",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ) versus parallel triple therapy (simultaneous sulfasalazine, methotrexate, and hydroxychloroquine). The study demonstrated no significant difference between the two groups; highly effective control was achieved in both groups, suggesting that the key to good control is intensive disease management beginning early in the disease course [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      was also incorporated in a study designed to try to identify the most effective approach to treatment of early RA. The study randomly assigned 508 patients to one of four different treatment groups (BeST trial) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/56\">",
"       56",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sequential monotherapy (group 1) &mdash; Group 1 patients were begun on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and subsequent steps for insufficient response included substitution with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , and then combinations.",
"     </li>",
"     <li>",
"      Step-up combination therapy (group 2) &mdash; Group 2 patients started with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and for insufficient response had",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      added, then",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      added, and then",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      added; other combinations were used subsequently.",
"     </li>",
"     <li>",
"      Initial combination therapy with tapered high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (group 3) &mdash; Group 3 began treatment with simultaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , and prednisone",
"     </li>",
"     <li>",
"      Initial combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (group 4) &mdash; Group 4 began with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and infliximab",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial combination therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (group 3) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (group 4) produced earlier functional improvement and was associated with less radiographic damage than sequential monotherapy (group 1) or step-up combination therapy (group 2). Early aggressive initiation of treatment with a combination of agents was more important than any other strategy in this trial &ndash; except for the possible benefit of infliximab specifically for radiographic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      European Investigators Network compared the efficacy and safety of etanercept and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      alone and in combination in a randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/66\">",
"       66",
"      </a>",
"      ]. For all efficacy variables assessed, etanercept alone or in combination with sulfasalazine had significant improvement in disease activity when compared with sulfasalazine alone at 24 weeks and at two years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/66,67\">",
"       66,67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recent studies and others are consistent with the view that in patients with RA, the most beneficial approach involves goal-driven, dynamic treatment towards tight control of disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     GENETIC POLYMORPHISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of disease-modifying antirheumatic drugs (DMARDs) is the foundation of treatment in rheumatoid arthritis, yet there is significant variability in the efficacy and side effects seen among DMARD-treated patients. This is a burgeoning area of research that may someday allow clinicians greater predictive capacity in their therapeutic choices. A number of recent studies have attempted to determine the effect of genetic polymorphisms on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    in rheumatoid arthritis.",
"   </p>",
"   <p>",
"    In one study, polymorphic variations in the MTR, SLC19A1 and TYMS genes (all components of the folate pathway) were associated with better clinical response to combination DMARD regimens containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/69\">",
"     69",
"    </a>",
"    ]. Another study noted an association between the MTHFR 677T allele and statistically significant increased frequency of remission [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study assessed the MDR-1 gene product, P-glycoprotein, one of the most important transporters for drug delivery in humans. The TT-genotype of the 3435C&gt;T MDR-1 gene polymorphism was associated with higher remission rates in rheumatoid patients treated with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies using human cell cultures have suggested that T cells may develop resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    by overexpression of a drug efflux pump, the multidrug resistance transporter",
"    <span class=\"nowrap\">",
"     BRCP/ABCG2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/27/2490/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Though this finding may be clinically relevant there is, as yet, no evidence that loss of effectiveness in patients with rheumatoid arthritis is mediated in this manner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"       \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with RA in whom disease-modifying antirheumatic agents are required,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    is a useful agent because of the following properties:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The dosages and toxicities are well known.",
"     </li>",
"     <li>",
"      The agent has a fairly rapid onset of action.",
"     </li>",
"     <li>",
"      Some evidence suggests that it may retard radiographic joint erosion.",
"     </li>",
"     <li>",
"      The drug is effective in patients of all ages, disease duration, and seroreactivity.",
"     </li>",
"     <li>",
"      It appears to be safe with regard to pregnancy and has no significant drug interactions.",
"     </li>",
"     <li>",
"      It can be used safely in combination therapy with a wide variety of other disease modifying drugs; some of these combinations may be more effective than single agents utilized alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Dahlia T Carr, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/1\">",
"      Amos RS. The history of the use of sulphasalazine in rheumatology. Br J Rheumatol 1995; 34 Suppl 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/2\">",
"      SVARTZ N. The treatment of rheumatic polyarthritis with acid azo compounds. Rheumatism 1948; 4:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/3\">",
"      Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. Br J Rheumatol 1997; 36:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/4\">",
"      Sinclair RJ, Duthie JJ. Salazopyrin in the Treatment of Rheumatoid Arthritis. Ann Rheum Dis 1949; 8:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/5\">",
"      McConkey B, Amos RS, Durham S, et al. Sulphasalazine in rheumatoid arthritis. Br Med J 1980; 280:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/6\">",
"      Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) 1983; 287:1102.",
"     </a>",
"    </li>",
"    <li>",
"     Azulfidine, EN-Tabs. In: Physicians Desk Reference, 52nd ed, Medical Economics Company, Montvale, NJ 1998. p.2239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/8\">",
"      Smedeg&aring;rd G, Bj&ouml;rk J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl 2:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/9\">",
"      Bird HA. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis? Br J Rheumatol 1995; 34 Suppl 2:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/10\">",
"      Pullar T, Hunter JA, Capell HA. Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J (Clin Res Ed) 1985; 290:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/11\">",
"      Taggart AJ, Neumann VC, Hill J, et al. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis? Drugs 1986; 32 Suppl 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/12\">",
"      Volin MV, Campbell PL, Connors MA, et al. The effect of sulfasalazine on rheumatoid arthritic synovial tissue chemokine production. Exp Mol Pathol 2002; 73:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/13\">",
"      Astbury C, Hill J, Bird HA. Co-trimoxazole in rheumatoid arthritis: a comparison with sulphapyridine. Ann Rheum Dis 1988; 47:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/14\">",
"      Cronstein BN. Therapeutic cocktails for rheumatoid arthritis: the mixmaster's guide. Arthritis Rheum 2004; 50:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/15\">",
"      Morabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998; 101:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/16\">",
"      Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/17\">",
"      Lee CK, Lee EY, Chung SM, et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum 2004; 50:3831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/18\">",
"      Rodenburg RJ, Ganga A, van Lent PL, et al. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum 2000; 43:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/19\">",
"      Hirohata S, Ohshima N, Yanagida T, Aramaki K. Regulation of human B cell function by sulfasalazine and its metabolites. Int Immunopharmacol 2002; 2:631.",
"     </a>",
"    </li>",
"    <li>",
"     Dougados M. Sulfasalazine. In: Therapy of Systemic Rheumatic Disorders, van de Putte LBA, Furst DE, Williams HJ, van Riel PLCM (Eds), Marcel Dekker, New York 1998. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/21\">",
"      Fuchs HA. Use of sulfasalazine in rheumatic diseases. Bull Rheum Dis 1997; 46:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/22\">",
"      Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/23\">",
"      Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003; 62:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/24\">",
"      Jobanputra P, Amarasena R, Maggs F, et al. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord 2008; 9:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/25\">",
"      Amos RS, Pullar T, Bax DE, et al. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) 1986; 293:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/26\">",
"      Farr M, Scott DG, Bacon PA. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine. Drugs 1986; 32 Suppl 1:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/27\">",
"      Jansen G, van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004; 50:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/28\">",
"      Tanaka E, Taniguchi A, Urano W, et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002; 29:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/29\">",
"      Denissen NH, Peters JG, Masereeuw R, Barrera P. Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis? Scand J Rheumatol 2008; 37:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/30\">",
"      Mut SE, Kutlu G, Ucler S, et al. Reversible encephalopathy due to sulfasalazine. Clin Neuropharmacol 2008; 31:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/31\">",
"      Komatsuda A, Okamoto Y, Hatakeyama T, et al. Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus. Clin Rheumatol 2008; 27:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/32\">",
"      van Riel PL, van Gestel AM, van de Putte LB. Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl 2:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/33\">",
"      Bax DE, Amos RS. Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash. Ann Rheum Dis 1986; 45:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/34\">",
"      Sulfasalazine in early rheumatoid arthritis. The Australian Multicentre Clinical Trial Group. J Rheumatol 1992; 19:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/35\">",
"      Hannonen P, M&ouml;tt&ouml;nen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993; 36:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/36\">",
"      Pinals RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 1986; 29:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/37\">",
"      Weinblatt ME, Reda D, Henderson W, et al. Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J Rheumatol 1999; 26:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/38\">",
"      Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988; 31:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/39\">",
"      Pullar T, Hunter JA, Capell HA. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis 1987; 46:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/40\">",
"      van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/41\">",
"      van der Heijde DM, van Riel PL, Nuver-Zwart IH, van de Putte LB. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet 1990; 335:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/42\">",
"      Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/43\">",
"      Strand V, Scott DL, Emery P, et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005; 32:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/44\">",
"      Capell HA. Clinical efficacy of sulphasalazine--a review. Br J Rheumatol 1995; 34 Suppl 2:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/45\">",
"      Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990; 33:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/46\">",
"      Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992; 35:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/47\">",
"      Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/48\">",
"      Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/49\">",
"      Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med 2009; 151:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/50\">",
"      Englert HJ, Hughes GR, Walport MJ. Sulphasalazine and regression of rheumatoid nodules. Ann Rheum Dis 1987; 46:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/51\">",
"      van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2007; 66:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/52\">",
"      O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/53\">",
"      O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/54\">",
"      Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/55\">",
"      Haagsma CJ, van Riel PL, de Rooij DJ, et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol 1994; 33:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/56\">",
"      Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/57\">",
"      Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/58\">",
"      M&ouml;tt&ouml;nen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/59\">",
"      Korthals-de Bos I, Van Tulder M, Boers M, et al. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone. J Rheumatol 2004; 31:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/60\">",
"      van Tuyl LH, Boers M, Lems WF, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010; 69:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/61\">",
"      Capell HA, Madhok R, Porter DR, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007; 66:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/62\">",
"      Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004; 50:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/63\">",
"      Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009; 60:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/64\">",
"      Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008; 58:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/65\">",
"      Weisman MH. Progress toward the cure of rheumatoid arthritis? The BeSt study. Arthritis Rheum 2005; 52:3326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/66\">",
"      Combe B, Codreanu C, Fiocco U, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 2006; 65:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/67\">",
"      Combe B, Codreanu C, Fiocco U, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis 2009; 68:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/68\">",
"      Klarenbeek NB, Allaart CF, Kerstens PJ, et al. The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol 2009; 21:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/69\">",
"      James HM, Gillis D, Hissaria P, et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol 2008; 35:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/70\">",
"      Pawlik A, Kurzawski M, Gawronska-Szklarz B, et al. The effect of 677C&gt;T and 1298A&gt;C MTHFR polymorphisms on sulfasalazine treatment outcome in rheumatoid arthritis. Braz J Med Biol Res 2009; 42:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/71\">",
"      Drozdzik M, Rudas T, Pawlik A, et al. The effect of 3435C&gt;T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 2006; 62:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/72\">",
"      van der Heijden J, de Jong MC, Dijkmans BA, et al. Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis 2004; 63:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/27/2490/abstract/73\">",
"      van der Heijden J, de Jong MC, Dijkmans BA, et al. Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis 2004; 63:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7524 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-C55D250E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2490=[""].join("\n");
var outline_f2_27_2490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Liver function abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Leukopenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Megaloblastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gender-specific effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other adverse events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MEASURES TO MINIMIZE SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Desensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Relative efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      GENETIC POLYMORPHISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7524\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7524|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_27_2491="Shoulder range of motion";
var content_f2_27_2491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approximate normal shoulder range of motion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Abduction",
"       </td>",
"       <td>",
"        180&ordm;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adduction",
"       </td>",
"       <td>",
"        45&ordm;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexion",
"       </td>",
"       <td>",
"        135&ordm;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extension",
"       </td>",
"       <td>",
"        45&ordm;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Internal rotation",
"       </td>",
"       <td>",
"        70&ordm;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        External rotation",
"       </td>",
"       <td>",
"        45&ordm;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2491=[""].join("\n");
var outline_f2_27_2491=null;
var title_f2_27_2492="Self administered CGA tool";
var content_f2_27_2492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Primarily self-administered comprehensive geriatric assessment tool*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Domain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Functional status",
"       </td>",
"       <td>",
"        1) Activities of Daily Living [Subscale of Medical Outcomes Study Physical Health Scale]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2) Instrumental Activities of Daily Living [Subscale of the OARS]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3) Karnofsky performance status (Physician-Rated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4) Karnofsky performance status (Patient-Rated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5) Timed Up and Go",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6) Number of falls in last six months",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Comorbidity",
"       </td>",
"       <td>",
"        Physical Health Section [Subscale of the OARS]",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cognition",
"       </td>",
"       <td>",
"        Blessed Orientation-Memory-Concentration Test",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Psychological",
"       </td>",
"       <td>",
"        Hospital Anxiety and Depression Scale",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Social functioning",
"       </td>",
"       <td>",
"        Medical Outcomes Study Social Activity Limitations Measure",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Social support",
"       </td>",
"       <td>",
"        Medical Outcomes Study Social Support Survey: Emotional/Information &amp; Tangible Subscales",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Nutrition",
"       </td>",
"       <td>",
"        1) Body mass index",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2) Percent unintentional weight loss in the last 6 months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OARS: Older Americans Resources and Services.",
"     <br/>",
"     * Also captures information on demographics and cancer characteristics.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2492=[""].join("\n");
var outline_f2_27_2492=null;
var title_f2_27_2493="Differential diagnosis of pediatric limp by age and duration";
var content_f2_27_2493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of limp in children by age and duration of symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        All ages",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Preschool",
"        </p>",
"        <p>",
"         (1 to 5 yrs)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         School-age",
"        </p>",
"        <p>",
"         (5 to 12 yrs)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Adolescent",
"        </p>",
"        <p>",
"         (13 to 19 yrs)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Acute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Contusion",
"        </p>",
"        <p>",
"         Foot foreign body",
"        </p>",
"        <p>",
"         Fracture",
"        </p>",
"        <p>",
"         Lyme arthritis*",
"        </p>",
"        <p>",
"         Osteomyelitis",
"        </p>",
"        <p>",
"         Poor shoe fit",
"        </p>",
"        <p>",
"         Reactive arthritis",
"        </p>",
"        <p>",
"         Septic arthritis",
"        </p>",
"        <p>",
"         Transient synovitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Child abuse",
"        </p>",
"        <p>",
"         Hand-foot-mouth disease (enterovirus infection)",
"        </p>",
"        <p>",
"         Hemarthrosis (hemophilia)",
"        </p>",
"        <p>",
"         Henoch Sh&ouml;nlein purpura",
"        </p>",
"        <p>",
"         Immunization (IM shot)",
"        </p>",
"        <p>",
"         Salter I fracture",
"        </p>",
"        <p>",
"         Septic hip",
"        </p>",
"        <p>",
"         Toddler's fracture",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Salter I fracture",
"        </p>",
"        <p>",
"         Myositis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Sprain or strain",
"        </p>",
"        <p>",
"         Tendonitis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Chronic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Rheumatic disease",
"        </p>",
"        <p>",
"         (Preschool: systemic JIA;",
"        </p>",
"        <p>",
"         School-age: JIA, dermatomyositis, acute rheumatic fever;",
"        </p>",
"        <p>",
"         Adolescent: IBD, SLE)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Blount disease",
"        </p>",
"        <p>",
"         Cerebral palsy",
"        </p>",
"        <p>",
"         Developmental dysplasia of the hip",
"        </p>",
"        <p>",
"         Discitis",
"        </p>",
"        <p>",
"         K&ouml;hler disease",
"        </p>",
"        <p>",
"         Leg length discrepancy",
"        </p>",
"        <p>",
"         Vertical talus",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Avascular necrosis of the hip (Legg-Calve-Perthe disease)",
"        </p>",
"        <p>",
"         Baker cyst",
"        </p>",
"        <p>",
"         K&ouml;hler disease",
"        </p>",
"        <p>",
"         Leukemia",
"        </p>",
"        <p>",
"         Spinal dysraphism (tethered cord)",
"        </p>",
"        <p>",
"         Tarsal coalition",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Chondromalacia of the patella",
"        </p>",
"        <p>",
"         CRPS",
"        </p>",
"        <p>",
"         Gonoccoccal arthritis",
"        </p>",
"        <p>",
"         Herniated lumbar vertebral disc",
"        </p>",
"        <p>",
"         Hypermobility syndrome",
"        </p>",
"        <p>",
"         Osteochondritis dissecans",
"        </p>",
"        <p>",
"         Overuse syndromes, Osgood-Schlatter disease",
"        </p>",
"        <p>",
"         Scoliosis",
"        </p>",
"        <p>",
"         Slipped capital femoral epiphysis",
"        </p>",
"        <p>",
"         Spinal dysraphism (tethered cord)",
"        </p>",
"        <p>",
"         Spondylolisthesis",
"        </p>",
"        <p>",
"         Tumor",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CRPS: complex regional pain syndrome; IBD: inflammatory bowel disease; IM: intramuscular; JIA: juvenile idiopathic arthritis; SLE: systemic lupus erythematosus.",
"     <br>",
"      * In areas endemic for Lyme disease.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2493=[""].join("\n");
var outline_f2_27_2493=null;
var title_f2_27_2494="Systolic BP cardiovascular death HOT trial";
var content_f2_27_2494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Systolic pressure and cardiovascular mortality in HOT trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 332px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated incidence (95 percent CI) of cardiovascular mortality in relation to achieved mean systolic blood pressure in the HOT trial. The systolic pressure at the lowest point of the curve is indicated (minimum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hansson L, Zanchetti A, Carruthers SG, et al. Lancet 1998; 351:1755.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2494=[""].join("\n");
var outline_f2_27_2494=null;
var title_f2_27_2495="Pharyngocele AP Ba swallow";
var content_f2_27_2495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pharyngocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior-posterior view of the hypopharynx during a barium swallow shows two lateral pharyngoceles (P) which have developed immediately above the esophageal inlet (E).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_27_2495=[""].join("\n");
var outline_f2_27_2495=null;
